BioSig Technologies (NASDAQ:BSGM) named Barry Keenan as VP of engineering to head up the company’s advanced product development.
Dr. Keenan has more than 20 years of experience in R&D, product development and commercialization, and deep industry expertise in a range of sectors, including neuromodulation, deep brain stimulation, sensing, imaging and cardiac pacing.
Since 2014, Dr. Keenan has been actively involved with the Alfred Mann Foundation for Scientific Research as CTO and VP for R&D, as well as a board member of the Alfred Mann Institute for Biomedical Engineering. During his tenure with the foundation, he managed an R&D department of over 40 scientists and engineers.
A biomedical engineer by training, Dr. Keenan spent more than nine years at Medtronic Diabetes, where he was responsible for algorithm development of the MiniMed Paradigm Veo insulin pump and iPro2 Professional continuous glucose Monitor, and clinical evaluation of the MiniMed 670G, the world’s first artificial pancreas.
“Barry’s second-to-none academic training and industry expertise are very hard to come by, and we are particularly impressed with his achievements in neuromodulation,” Kenneth Londoner, chairman and CEO of BioSig, said in a statement. “As we accelerate our research activities, we need strong engineering leadership and commercial expertise to grow our product development.”
